The effect of sitaglibtin (DPP4 inhibitor) administration in type 2 diabetes patients under insulin therapy regarding the weight, Lipid profile changes and blood glucose control

The effect of DPP4 inhibitor administration in type 2 diabetes patients under insulin therapy regarding the weight and blood glucose control

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191231045959N2

Enrollment

Registered

2020-04-24

Start date

2019-06-22

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: The first group received 100 mg of sitagliptin (DPP4 inhubitor) (Construction pharmaceutical company Abidi) daily with insulin therapy for 3 months. Intervention 2:

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients older than 18 years Type 2 diabetic patients treated with insulin therapy (insulin therapy over the past 6 months.) HbA1C>=7

Exclusion criteria

Exclusion criteria: Heart disease ( Ischemic heart disease, Congenital adrenal hyperplasia and valvular disease) Pregnancy and lactation liver Diseases Renal failure Diseases

Design outcomes

Primary

Measure	Time frame
Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Weigh.;Fast blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Triglyceride. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Cholestrol. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;High-Density Lipoprotein. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;2hpp. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;HbA1C. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.	—

Measure

Time frame

Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Weigh.;Fast blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Triglyceride. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Cholestrol. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;High-Density Lipoprotein. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;2hpp. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;HbA1C. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Vahideh Sadra

Tabriz University of Medical Sciences

vahideh.sadra@gail.com+98 41 3334 8939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026